---
title: "Coverage initiated with a target price of 80,000 won, expecting MG and GD clinical results in 2027. — 하나증권 제약/바이오 김선아 — DecisionGateway"
description: "commitment by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea"
meta:
  "og:description": "commitment by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Coverage initiated with a target price of 80,000 won, expecting MG and GD clinical results in 2027. — 하나증권 제약/바이오 김선아 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

commitment

# **Coverage initiated with a target price of 80,000 won, expecting MG and GD clinical results in 2027.**

A commitment by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *커버리지 개시: 목표 주가 80,000원, ‘27년에 MG와 GD 임상 발표를 기대하며*

hanaresearchPublished 2026-11-10 [ Read source](https://t.me/hanaresearch/20929)

## **Discussion**

## **Related claims**

[**실적 추정치와 적정 밸류에이션(12MF PER 8배->7배)을 하향 조정해 목표주가를 43만원에서 36.5만원으로 하향했다.**하나증권 · commitment](https://dgw.tmarket.io/claims/01a1ceb6-59b7-7505-80d2-b535a5d76df7) [**한미약품에 대해 투자의견 BUY, 목표주가 72만원(상향)을 제시했다.**하나증권 · prediction](https://dgw.tmarket.io/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a) [**Topline data from the Graves' disease (GD) Phase 2b and myasthenia gravis (MG) Phase 3 registrational trials are expected in 2027.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965) [**From 4Q onward, price increase effects, overseas coverage expansion, and securing bio cost competitiveness through collaboration with ADM are expected.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b6-46cf-722d-a5e6-5e3ba88d8072) [**From year-end, the D2T RA approval direction will be discussed with the FDA, and GD (Phase 2b) and MG (Phase 3) top-line results are scheduled for 2027.**하나증권 제약/바이오 김선아 · commitment](https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492) [**상기 두 가지 요인을 아직 주가에 반영하기는 이르다고 판단해 기존 삼원계 CAPA 기준으로 반영할 수 있는 최대가치 11조원 내에서의 트레이딩 접근을 권고한다.**하나증권 · commitment](https://dgw.tmarket.io/claims/01a1ceaf-844f-74fb-8487-37d24bd9fc58)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea#webpage","@type":"WebPage","description":"commitment by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation.","name":"Coverage initiated with a target price of 80,000 won, expecting MG and GD clinical results in 2027. — 하나증권 제약/바이오 김선아 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Coverage initiated with a target price of 80,000 won,…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/hanaresearch/20929","text":"커버리지 개시: 목표 주가 80,000원, ‘27년에 MG와 GD 임상 발표를 기대하며","url":"/claims/01a1d887-39d6-7025-b897-501eb5b9aeea"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.